



Dynavax to Webcast Presentation at Pacific Growth Equities 2005 Life Sciences Conference

BERKELEY, Calif., May 25, 2005 /PRNewswire-FirstCall via COMTEX/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President, CEO and Director, will present an overview of the company at the Pacific Growth Equities 2005 Life Sciences Growth Conference at the Mark Hopkins InterContinental hotel in San Francisco.

Dr. Dina's presentation will be webcast live at 8:00 am PT on Monday, June 6, 2005.

The webcast presentation may be accessed by visiting http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=DVAX&item_id=1074505

The presentation may also be accessed by visiting the Dynavax website at <http://www.Dynavax.com> under the Investors section where it will also be archived for 30 days following the presentation.

About Dynavax

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: a ragweed allergy immunotherapeutic, currently in a large-scale Phase 2/3 clinical trial, and in a supportive clinical trial in ragweed allergic children; a hepatitis B vaccine that is currently in a Phase 2/3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.

SOURCE Dynavax Technologies Corporation

Jane M. Green, PhD, Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or jgreen@dvax.com

<http://www.prnewswire.com>